ArticleInfection and immunity2002
Mutational analysis of ganglioside GM(1)-binding ability, pentamer formation, and epitopes of cholera toxin B (CTB) subunits and CTB/heat-labile enterotoxin B subunit chimeras.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Cholera toxin as a model ABArchives of toxicology · 2026Review
- A Modular Design of a Cholera Toxin B Subunit-Scaffolded Sub-Virion Nanoparticle Vaccine Against West Nile Virus.Microbial biotechnology · 2026Article
- Electrostatic Interaction Analysis Between GM3 and Insulin Receptor.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Orally delivered toxin-binding protein protects against diarrhoea in a murine cholera model.Nature communications · 2025Article
- Efficient Production of Self-Assembled Bioconjugate Nanovaccines againstNanomaterials (Basel, Switzerland) · 2024Article
- The Mutagenic Plasticity of the Cholera Toxin B-Subunit Surface Residues: Stability and Affinity.Toxins · 2024Article
- Harnessing Pentameric Scaffold of Cholera Toxin B (CTB) for Design of Subvirion Recombinant Dengue Virus Vaccine.Vaccines · 2024Article
- Characterization and utility of two monoclonal antibodies to cholera toxin B subunit.Scientific reports · 2023Article
- Cell-Free Systems Enable the Production of ABToxins · 2022Article
- Cholera Toxin as a Probe for Membrane Biology.Toxins · 2021Review
- Isolation and detection of a KDEL-tagged recombinant cholera toxin B subunit fromProcess biochemistry (Barking, London, England) · 2021Article
- Streamlined chemoenzymatic total synthesis of prioritized ganglioside cancer antigens.Organic & biomolecular chemistry · 2018Article
- Development of Adjuvant-Free Bivalent Food Poisoning Vaccine by Augmenting the Antigenicity ofFrontiers in immunology · 2018Article
- Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.Mucosal immunology · 2017Article
- Sequential One-Pot Multienzyme Chemoenzymatic Synthesis of Glycosphingolipid Glycans.The Journal of organic chemistry · 2016Article
- Glycosphingolipid-Protein Interaction in Signal Transduction.International journal of molecular sciences · 2016Review
- Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.Oncotarget · 2015Article
- Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.PloS one · 2014Article
- Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?Cancers · 2013Article
- Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.Veterinary immunology and immunopathology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Variants of cholera toxin B subunit (CTB) were made by bisulfite- and oligonucleotide-directed mutagenesis of the ctxB gene. Variants were screened by a radial passive immune hemolysis assay (RPIHA) for loss of binding to sheep erythrocytes (SRBC). Variant CTBs were characterized for the formation of immunoreactive pentamers, the ability to bind ganglioside GM(1) in vitro, and reactivity with a panel of monoclonal anti-CTB antibodies. Substitutions at eight positions (i.e., positions 22, 29, 36, 45, 64, 86, 93, and 100) greatly reduced the yield of immunoreactive CTB. RPIHA-negative substitution variants that formed immunoreactive pentamers were obtained for residues 12, 33, 36, 51, 52 + 54, 91, and 95. Tyrosine-12 was identified as a novel residue important for GM(1) binding since, among all of the novel variants isolated with altered RPIHA phenotypes, only CTB with aspartate substituted for tyrosine at position 12 failed to bind significantly to ganglioside GM(1) in vitro. In contrast, CTB variants with single substitutions for several other residues (Glu-51, Lys-91, and Ala-95) that participate in GM(1) binding, based on the crystal structure of CTB and the oligosaccharide of GM(1), were not appreciably altered in their ability to bind GM(1) in vitro, even though they showed altered RPIHA phenotypes and did not bind to SRBC. Hybrid B genes made by fusing ctxB and the related Escherichia coli heat-labile enterotoxin eltB genes at codon 56 produced CTB variants that had 7 or 12 heat-labile enterotoxin B residue substitutions in the amino or carboxyl halves of the monomer, respectively, each of which which also bound GM(1) as well as wild-type CTB. This collection of variant CTBs in which 47 of the 103 residues were substituted was used to map the epitopes of nine anti-CTB monoclonal antibodies (MAbs). Each MAb had a unique pattern of reactivity with the panel of CTB variants. Although no two of the epitopes recognized by different MAbs were identical, most of the single amino acid substitutions that altered the immunoreactivity of CTB affected more that one epitope. The tertiary structures of the epitopes of these anti-CTB MAbs are highly conformational and may involve structural elements both within and between CTB monomers. Substitution of valine for alanine at positions 10 and 46 had dramatic effects on the immunoreactivity of CTB, affecting epitopes recognized by eight or six MAbs, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.